Investment Centers of America Inc. decreased its holdings in shares of GlaxoSmithKline PLC (NYSE:GSK) by 29.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 24,957 shares of the pharmaceutical company’s stock after selling 10,218 shares during the quarter. Investment Centers of America Inc.’s holdings in GlaxoSmithKline PLC were worth $1,070,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. FMR LLC boosted its stake in GlaxoSmithKline PLC by 11.7% during the 1st quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company’s stock valued at $996,452,000 after purchasing an additional 2,482,009 shares during the period. Fisher Asset Management LLC boosted its stake in GlaxoSmithKline PLC by 4.7% during the 2nd quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock valued at $540,483,000 after purchasing an additional 564,519 shares during the period. Bank of America Corp DE boosted its stake in GlaxoSmithKline PLC by 15.8% during the 1st quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock valued at $288,780,000 after purchasing an additional 934,928 shares during the period. Federated Investors Inc. PA boosted its stake in GlaxoSmithKline PLC by 22.7% during the 2nd quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock valued at $194,521,000 after purchasing an additional 833,501 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in GlaxoSmithKline PLC by 42.7% during the 1st quarter. Renaissance Technologies LLC now owns 4,402,100 shares of the pharmaceutical company’s stock valued at $185,593,000 after purchasing an additional 1,316,600 shares during the period. Hedge funds and other institutional investors own 9.29% of the company’s stock.

Several analysts recently weighed in on GSK shares. Zacks Investment Research downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Monday, July 24th. BidaskClub cut GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. ValuEngine cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Berenberg Bank raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a report on Friday, May 26th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $46.00.

Shares of GlaxoSmithKline PLC (NYSE GSK) traded down 0.27% during trading on Friday, hitting $40.24. The stock had a trading volume of 3,006,781 shares. The stock’s 50-day moving average is $39.80 and its 200-day moving average is $41.77. The stock has a market capitalization of $98.35 billion, a P/E ratio of 39.76 and a beta of 1.03. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The company had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. Analysts predict that GlaxoSmithKline PLC will post $2.87 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be given a $0.491 dividend. This represents a $1.96 dividend on an annualized basis and a dividend yield of 4.88%. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date is Wednesday, August 9th. GlaxoSmithKline PLC’s payout ratio is presently 197.00%.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-position-trimmed-by-investment-centers-of-america-inc/1566427.html.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.